Get the Stockscreener App
39.82
1.37%
0.54
Enliven Therapeutics Inc stock is traded at $39.82, with a volume of 503.24K.
It is up +1.37% in the last 24 hours and down -25.37% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$39.28
Open:
$39.48
24h Volume:
503.24K
Relative Volume:
0.42
Market Cap:
$2.92B
Revenue:
Net Income/Loss:
$-98.78M
P/E Ratio:
-23.93
EPS:
-1.6638
Net Cash Flow:
$-65.60M
1W Performance:
-1.99%
1M Performance:
-25.37%
6M Performance:
-9.40%
1Y Performance:
+83.25%
1-Day Range:
$38.49
$40.23
1-Week Range:
$38.51
$42.06
52-Week Range:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
39.82 | 2.92B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-26 | Initiated | Morgan Stanley | Overweight |
| Oct-01-26 | Initiated | JP Morgan | Overweight |
| Aug-18-26 | Initiated | Barclays | Overweight |
| Aug-18-26 | Initiated | William Blair | Outperform |
| Jun-09-26 | Initiated | Stifel | Buy |
| May-12-26 | Initiated | Guggenheim | Buy |
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares. - Stock Titan
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares. - stocktitan.net
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock - Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares - Stock Titan
Enliven Therapeutics (Nasdaq:ELVN)Stock Analysis - Simply Wall Street
Enliven Therapeutics (ELVN) officer lines up new stock sale - Stock Titan
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics to Present at Upcoming Investor Conferences - finance.yahoo.com
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire
Enliven will present leukemia drug data twice at a Houston meeting - Stock Titan
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com India
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com UK
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com UK
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JEFFREY GARLAND | Director |
Oct 01 '26 |
Proposed Sale |
46.67 |
13,000 |
606,719 |
0 |
| Garland J. Scott | Director |
Oct 01 '26 |
Sale |
46.67 |
13,000 |
606,719 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Option Exercise |
2.48 |
5,000 |
12,400 |
30,000 |
| Hohl Benjamin | Officer |
Sep 17 '26 |
Proposed Sale |
49.12 |
12,036 |
591,208 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Sale |
50.35 |
5,000 |
251,754 |
25,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 17 '26 |
Sale |
50.35 |
6,018 |
303,003 |
38,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
14.85 |
3,982 |
59,133 |
44,018 |
| Heyman Richard A. | resigned from BOD |
Sep 04 '26 |
Proposed Sale |
59.28 |
38,000 |
2,252,830 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Aug 17 '26 |
Sale |
58.59 |
5,000 |
292,931 |
25,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Aug 17 '26 |
Sale |
58.58 |
6,018 |
352,551 |
40,036 |
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):